Genmab Valuation
Is GMAB undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of GMAB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: GMAB (€262.9) is trading below our estimate of fair value (€861.31)
Significantly Below Fair Value: GMAB is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for GMAB?
Other financial metrics that can be useful for relative valuation.
| What is GMAB's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | kr.126.52b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 6x |
| Enterprise Value/EBITDA | 17.8x |
| PEG Ratio | 1.3x |
Price to Earnings Ratio vs Peers
How does GMAB's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 47x | ||
NBIX Neurocrine Biosciences | 38.9x | 25.6% | US$13.8b |
HZNP Horizon Therapeutics | 60.8x | 16.4% | US$26.6b |
BMRN BioMarin Pharmaceutical | 77x | 29.5% | US$15.3b |
300122 Chongqing Zhifei Biological Products | 11.2x | 22.8% | CN¥84.0b |
GMAB Genmab | 29.2x | 21.8% | €126.5b |
Price-To-Earnings vs Peers: GMAB is good value based on its Price-To-Earnings Ratio (29.2x) compared to the peer average (47.1x).
Price to Earnings Ratio vs Industry
How does GMAB's PE Ratio compare vs other companies in the European Biotechs Industry?
Price-To-Earnings vs Industry: GMAB is good value based on its Price-To-Earnings Ratio (29.2x) compared to the European Biotechs industry average (31.7x).
Price to Earnings Ratio vs Fair Ratio
What is GMAB's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 29.2x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate GMAB's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €262.90 | €330.16 +25.6% | 15.6% | €402.21 | €222.83 | n/a | 17 |
| Apr ’25 | €276.10 | €330.02 +19.5% | 16.0% | €427.75 | €222.86 | n/a | 18 |
| Mar ’25 | €271.20 | €328.54 +21.1% | 16.3% | €427.91 | €222.94 | n/a | 18 |
| Feb ’25 | €257.40 | €337.24 +31.0% | 14.2% | €428.00 | €236.81 | n/a | 18 |
| Jan ’25 | €288.50 | €353.85 +22.7% | 13.1% | €428.00 | €268.34 | n/a | 18 |
| Dec ’24 | €289.90 | €360.37 +24.3% | 14.4% | €445.40 | €268.31 | n/a | 18 |
| Nov ’24 | €273.30 | €378.95 +38.7% | 14.8% | €459.74 | €263.38 | n/a | 18 |
| Oct ’24 | €334.60 | €388.36 +16.1% | 12.4% | €460.04 | €263.55 | n/a | 18 |
| Sep ’24 | €357.30 | €385.87 +8.0% | 13.6% | €460.17 | €263.62 | n/a | 20 |
| Aug ’24 | €375.90 | €384.44 +2.3% | 15.5% | €456.24 | €218.05 | n/a | 20 |
| Jul ’24 | €346.80 | €381.04 +9.9% | 15.7% | €456.52 | €218.19 | n/a | 19 |
| Jun ’24 | €368.50 | €384.94 +4.5% | 15.3% | €456.55 | €218.20 | n/a | 20 |
| May ’24 | €372.70 | €389.90 +4.6% | 15.7% | €470.65 | €218.20 | €262.90 | 18 |
| Apr ’24 | €348.10 | €389.90 +12.0% | 15.7% | €470.65 | €218.20 | €276.10 | 18 |
| Mar ’24 | €351.00 | €398.24 +13.5% | 13.3% | €483.53 | €288.77 | €271.20 | 18 |
| Feb ’24 | €356.20 | €406.30 +14.1% | 13.3% | €484.02 | €289.07 | €257.40 | 18 |
| Jan ’24 | €396.50 | €408.47 +3.0% | 12.6% | €479.07 | €288.92 | €288.50 | 19 |
| Dec ’23 | €428.20 | €401.82 -6.2% | 12.4% | €470.71 | €288.74 | €289.90 | 19 |
| Nov ’23 | €390.30 | €377.13 -3.4% | 11.5% | €439.51 | €262.09 | €273.30 | 20 |
| Oct ’23 | €331.70 | €375.17 +13.1% | 11.0% | €422.11 | €262.22 | €334.60 | 20 |
| Sep ’23 | €347.10 | €365.53 +5.3% | 12.8% | €422.00 | €262.16 | €357.30 | 21 |
| Aug ’23 | €347.50 | €356.85 +2.7% | 14.4% | €448.28 | €209.38 | €375.90 | 22 |
| Jul ’23 | €317.40 | €354.32 +11.6% | 14.3% | €448.86 | €209.65 | €346.80 | 21 |
| Jun ’23 | €278.50 | €355.30 +27.6% | 14.5% | €448.89 | €209.66 | €368.50 | 21 |
| May ’23 | €336.20 | €371.12 +10.4% | 12.7% | €438.90 | €268.85 | €372.70 | 20 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.